This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi (SNY) to Manufacture BioNTech's Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.
Top Research Reports for Facebook, Novo Nordisk & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Novo Nordisk (NVO), and SAP SE (SAP).
Merck's (MRK) Keytruda Gets EC Nod for MSI-H Colorectal Cancer
by Zacks Equity Research
The European Commission approves Merck's (MRK) Keytruda as a monotherapy for first-line treatment of patients with metastatic MSI-H or dMMR colorectal cancer.
J&J (JNJ) to Get the Ball Rolling for Pharma Q4 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while continued procedure stabilization is expected to have benefited the Medical Devices segment in the fourth quarter.
Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal
by Kinjel Shah
Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.
Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals
by Kinjel Shah
Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.
Merck (MRK) Gets Priority Tag for Pneumococcal Vaccine BLA
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine, V114 includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed conjugate vaccines.
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand
by Zacks Equity Research
Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.
The Zacks Analyst Blog Highlights: UnitedHealth Group, Netflix, Caterpillar, General Electric and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth Group, Netflix, Caterpillar, General Electric and GlaxoSmithKline
Top Stock Reports for UnitedHealth, Netflix & Caterpillar
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Netflix (NFLX), and Caterpillar (CAT).
5 Big ETF Stories of 2020 Worth Watching in 2021
by Sweta Killa
We discuss some of the events that dominated the headlines in 2020 and are worth watching in 2021.
Wall Street Stories That Hit Headlines in 2020
by Sweta Killa
With super-easy policies and vaccination, small-cap stocks like Liquidity Services (LQDT) and cyclical stocks like Nexstar Media (NXST), Deere & Company (DE) and BHP Billiton (BBL) are expected to benefit the most.
Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug
by Zacks Equity Research
Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.
Evergreen Tree of ETFs to Lighten Your Christmas
by Sweta Killa
The Christmas tree of top-ranked ETFs to brighten 2021 is now ready for investors. May it spread cheer!
U.S. Dollar to Remain Weak in 2021? ETFs to Gain
by Sanghamitra Saha
U.S. dollar is expected to remain weak in 2021, after being beaten down this year.
The Zacks Analyst Blog Highlights: AMZN, WMT, UNH, MS and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AMZN, WMT, UNH, MS and GSK
Amgen/AstraZeneca's Asthma Drug Misses Phase III Study Goal
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) plan to file regulatory applications for tezepelumab next year.
Top Research Reports for Amazon, Walmart & UnitedHealth
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com (AMZN), Walmart (WMT) and UnitedHealth Group (UNH).
Clovis' (CLVS) Rubraca Confirmatory Study Meets Endpoint
by Zacks Equity Research
Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $37.01, marking a -0.88% move from the previous day.
Merck (MRK) Gets FDA's Priority Review for Another Keytruda sBLA
by Zacks Equity Research
The FDA accepts Merck's (MRK) sBLA for Keytruda combo for first-line metastatic esophageal and gastroesophageal junction cancer, under a priority review. The FDA's verdict is awaited on Apr 13, 2021.
TIPS ETFs to Buy for 2021 on Inflation Trade
by Sweta Killa
The COVID-19 vaccines and their availability have raised the prospect of inflation as we move ahead into the next year.
Gilead's (GILD) CAR T Cell Therapy Tecartus Wins EC Nod
by Zacks Equity Research
Gilead (GILD) company, Kite, gets conditional marketing authorization for CAR T cell therapy, Tecartus.